Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting

Title: Olutasidenib for Mutated IDH1 Acute Myeloid Leukemia: Final Five-Year Results from the Phase 2 Pivotal Cohort Presenter: Jorge E. Cortes, M.D. - Long-term efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax - Data from a subgroup analyses of elderly R/R mIDH1 AML patients treated with olutasidenib shows consistent CR/CRh results - Overview of the Phase 1b trial of R289 in patient ...